This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT03838185 |
|---|---|
| Status | Completed |
| Phase | Phase 1 |
| Sponsor | Abrexa Pharmaceuticals, Inc. |
| Enrollment | 64 participants |
| Design | Interventional, Randomized, Sequential, Masking: Quadruple |
| Conditions | Alzheimer's Disease |
| Interventions | J147; Placebo |
| Start | Jan 22, 2019 |
| Primary completion | Feb 1, 2020 |
| Study completion | Feb 1, 2020 |
| Results posted | Not yet |
| Registry last updated | Sep 3, 2020 |
| Collaborators | IQVIA Pty Ltd |
Compounds on this site that cite this trial
What the registry says the trial is about
This Phase I clinical study is a randomized, double-blind, placebo-controlled, parallel-design study to thoroughly assess the safety profile and PK properties of J147 in healthy subjects. The study will include single ascending dose (SAD) in healthy young and elderly subjects.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Incidence of treatment-emergent adverse events | from pre-dose to 7+/-2 days post dose |
| Number of subjects with abnormal electrocardiogram | from pre-dose to 7+/-2 days post dose |
| Incidence of clinically significant changes in serum biomarker levels in a standard serum chemistry panel | from pre-dose to 7+/-2 days post dose |
| Incidence of clinically significant changes in hematological biomarker levels in a standard hematology panel | from pre-dose to 7+/-2 days post dose |
| Incidence of clinically significant changes in urine biomarker levels in a standard urinalysis panel | from pre-dose to 7+/-2 days post dose |
| Number of patients exhibiting changes in standard Physical Examination results | from pre-dose to 7+/-2 days post dose |
| Number of patients exhibiting changes in standard Neurological Examination results | from pre-dose to 7+/-2 days post dose |
7 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 3, 2026. See the trial changes feed for what has changed recently.
